Tebipenem pivoxil - Spero Therapeutics

Drug Profile

Tebipenem pivoxil - Spero Therapeutics

Alternative Names: L-084; ME1211; Orapenem; SPR-994; Tebipenem; Tebipenem-prodrug

Latest Information Update: 04 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth K.K.
  • Developer Meiji Seika Pharma; Spero Therapeutics
  • Class Antibacterials; Carbapenems; Esters; Small molecules; Thiazoles
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilus infections; Streptococcal infections
  • Phase I Urinary tract infections
  • Preclinical Gram-negative infections

Most Recent Events

  • 27 Sep 2018 Spero Therapeutics plans a pre-phase III meeting with US FDA in the fourth quarter of 2018
  • 27 Sep 2018 Final pharmacokinetics and adverse events data from a phase I trial in Urinary tract infections released by Spero Therapeutics
  • 02 Aug 2018 Spero Therapeutics completes a phase I trial for Urinary tract infections (In volunteers) in Australia (PO) (NCT03395249)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top